Peptides in 2TM · Survodutide
Episode 14 · 1:56 · English
Survodutide: weight and liver evidence
Follow Boehringer Ingelheim and Zealand Pharma’s survodutide through separate weight and MRI liver-fat studies. Examine the populations, treatment-discontinuation analyses, safety findings, and limits of each measurement.
English narration and optional captions. Captions use recognition-assisted timing with scientific terms corrected. Translated subtitles are not yet available for this episode.
Published . Evidence cutoff: October 14, 2026.
Behind the film: Survodutide references & context
Peptides in 2 — Episode 14: Weight and liver evidence. Evidence cutoff: October 14, 2026. Published October 14, 2026. World Peptide Foundation. Every experience matters.
Identity, origin and development
Survodutide, previously BI 456906, is an investigational once-weekly glucagon/GLP-1 receptor dual agonist. It is one peptide with activity at two receptor types, not two medicines mixed together. The film focuses on two distinct clinical endpoints rather than repeating the series' earlier hormone-origin explanations.
Boehringer Ingelheim and Zealand Pharma co-invented survodutide. Their partnership began in 2011; Boehringer has global development and commercialization responsibility. The film's Germany/Denmark labels identify the companies' research context, not exact invention locations or the geography of every clinical site. Clinical investigators are credited separately from the companies. Publication dates are not invention dates, and no trial author is called the sole inventor.
Primary company records: Zealand partnering history, 2023 interim presentation identifying co-invention, and current pipeline. Company descriptions of a drug's potential are not independent clinical conclusions.
Obesity evidence: SYNCHRONIZE-1
Carel W. le Roux and colleagues reported a randomized, double-blind phase 3 trial involving 725 adults without diabetes, with lifestyle counseling. At week 76, treatment-regimen estimates of mean weight reduction were 12.2% at 3.6 mg, 13.0% at 6.0 mg and 5.4% with placebo. This estimand incorporates early discontinuation, prohibited obesity medication use and prolonged escalation. It answers a different question from an analysis assuming continued treatment.
| Research arm | Mean reduction | 95% confidence interval, reduction magnitude |
|---|---|---|
| Survodutide 3.6 mg | 12.2% | 10.8–13.6% |
| Survodutide 6.0 mg | 13.0% | 11.6–14.4% |
| Placebo | 5.4% | 4.0–6.9% |
The underlying body-weight changes are negative. The film plots positive magnitudes of reduction, with true 95% confidence-interval whiskers. These are not individual response ranges. The zero-based axis extends to 20%. Values remain fixed for reading. Research doses identify trial arms; they are not treatment instructions.
le Roux CW, Wharton S, Startseva E, et al. New England Journal of Medicine 395:776–787 (2026), first online June 7. DOI 10.1056/NEJMoa2600751; PubMed 42253238. The University of Glasgow primary institutional record reproduces the abstract. Trial: NCT06066515.
Liver-fat evidence: SYNCHRONIZE-MASLD
Lee M. Kaplan and colleagues studied a separate population with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The article reports 218 randomized and 216 treated participants; the film keeps these counts distinct. At 48 weeks, the treatment-regimen estimate of participants reaching at least a 30% relative MRI-PDFF liver-fat reduction was 68.5% with survodutide versus 28.6% with placebo. It is a responder proportion, not the mean percentage of liver fat removed. The bar axis covers 0–100%.
MRI-PDFF means magnetic resonance imaging–proton density fat fraction; it measures liver fat. A change in this measurement does not itself prove reversal of fibrosis, a biopsy diagnosis, or a reduction in clinical liver events. The two study graphics are not combined into one outcome or a cross-study ranking. The studies have different populations and durations.
Kaplan LM, Startseva E, le Roux CW, et al. Nature Medicine 32:2948–2958 (2026). DOI 10.1038/s41591-026-04479-3; current primary article. Its August 25, 2026 author correction, DOI 10.1038/s41591-026-04650-w, was checked. It corrects investigator/affiliation details and typographical information; the film uses the updated record. Trial: NCT06309992.
Safety and uncertainty
Gastrointestinal symptoms were common in the trials and sometimes led to treatment stopping. The SYNCHRONIZE-1 abstract reports gastrointestinal events in 80.9%, 89.7% and 47.9% of the 3.6-mg, 6.0-mg and placebo arms, respectively. A brief film cannot reproduce every adverse event, discontinuation reason or subgroup finding. Consult the full publications and supplements. Weight and imaging results do not establish long-term safety, durable benefit for every patient or cardiovascular/mortality effects. No comparison with another medicine is inferred from separate trials.
Status at the cutoff
Survodutide remains investigational. The SYNCHRONIZE programme addresses obesity and related populations; LIVERAGE and LIVERAGE-Cirrhosis address metabolic dysfunction-associated steatohepatitis (MASH) with different fibrosis stages. Trials in these settings do not make the populations interchangeable. Development designations and positive trial results are not marketing approval or a guarantee of success. The current Zealand pipeline record identifies the programmes and investigational status.
The October 1, 2026 sponsor announcement on SYNCHRONIZE-2 concerns adults with type 2 diabetes. It was checked for current status, but its figures are not inserted into the film's SYNCHRONIZE-1 chart. The film uses published primary trial data for its numerical graphics. Future results and regulatory decisions can change this account.
Original artwork and visual interpretation
Four original images were generated specifically for this episode: an optical research bench, a magnet-cryostat-inspired laboratory scene, an MRI suite and an ultrasound/elastography-inspired probe with a calibration phantom. They are conceptual technology art, not photographs of actual Boehringer or Zealand facilities, documented trial equipment or real patient results. No scan or scientific result is embedded in the art. The depicted devices do not establish that those exact instruments were used in the trials.
The optical paths are an artistic research motif, not a diagram of peptide action. The cryostat is research context, not a manufacturing or receptor-assay claim. The MRI scene introduces imaging without inventing a patient scan. The probe scene does not demonstrate fibrosis reversal. All scientific values and labels are separately drawn from verified sources using code. No inferred atomic structure, simulated binding, glowing bead mechanism or recycled content illustration is used.
Each artwork appears once in the content sequence, with a subtle 2.5% camera move over the still image. It is presentation motion, not documentary footage of moving hardware. The two result graphics remain complete and static; their former pauses contain explanatory narration. The development-status panels are newly composed. The established WPF opening and closing brand image is retained. Montserrat uses the included SIL Open Font License.
Narration, sound and delivery
The content uses its original Tom narration; the ending uses one complete replacement performance of the same voice. No earlier episode voice clip or older closing is spliced in. Generation speed is 0.85, with no post-production voice acceleration. The graph pauses contain two explanatory transitions. The final section is replaced with one complete closing recording. This preserves natural speech speed while allowing viewers to inspect the results. No real investigator's voice is cloned.
A new restrained instrumental score uses nylon-string guitar harmonics, viola textures, bass flute tones and ambient pads. No earlier episode music is reused. Paid video generation: none. Rendering, typography, diagrams and audio assembly are local production processes.
The published MP4 is 116 seconds, 1920×1080, 24 fps, stereo AAC. The complete spoken closing ends before the final fade: “Peptides in 2. World Peptide Foundation. Every experience matters.” English SRT and VTT files are optional separate tracks. Their timing uses recognition-assisted word timestamps, adjusted for the reading pauses; scientific spellings and number formatting are corrected. The transcript preserves the requested spoken text.
The source pack includes all artwork and prompts, provenance, narration, original score, brand image, production scripts, measured timing, captions, transcript, plan, thumbnail, website copy and validation. Temporary signed URLs, upload helpers and downloaded full publications/recognition engines are excluded. Technical checks cover full decode, all eight narration windows, reading-pause placement, complete closing, graphic values and intervals, caption bounds and new-art hashes.
Educational information, not medical advice. WPF does not sell peptides. Source checks and technical verification are not independent human scientific review or institutional endorsement. Scientific studies and contributed experiences remain different types of evidence. Corrections and primary-source suggestions: admin@worldpeptidefoundation.org.
Final closing: one uninterrupted Tom recording covers the takeaway, complete WPF sign-off. Only two long silent breaths are shortened; no spoken audio is sped up or slowed down. One soft dissolve moves from the summary to the WPF card, with no return to another content screen. The soundtrack and picture before 1:41 remain as accepted.
The preview of the following film is removed from the status screen, voice track and captions. The sign-off follows the final takeaway directly.
Read the English transcript
Survodutide brings GLP-one and glucagon receptor activity into one peptide. Researchers are testing this combination for obesity and metabolic liver disease.
It emerged from Boehringer Ingelheim and Zealand Pharma's partnership. Boehringer now leads global development, linking German and Danish research.
A phase three trial followed seven hundred twenty-five adults without diabetes for seventy-six weeks. Average weight reductions were twelve point two and thirteen percent, versus five point four percent with placebo. Body weight does not directly measure liver fat.
Separate liver research used magnetic resonance imaging to measure fat. Lee Kaplan and colleagues treated two hundred sixteen adults with obesity and at-risk fatty liver disease.
At forty-eight weeks, sixty-eight point five percent reached at least a thirty-percent relative liver-fat reduction, versus twenty-eight point six percent with placebo. These analyses include treatment discontinuation. Tolerability can affect whether people continue treatment.
Gastrointestinal symptoms were common and sometimes led to treatment stopping. Less liver fat does not, by itself, prove reversal of fibrosis.
At the October fourteen, twenty twenty-six cutoff, survodutide remains investigational. Longer-term studies must establish lasting benefits and risks.
Weight and liver-fat measurements are part of the evidence. Lasting health benefits remain the key question. Peptides in 2. World Peptide Foundation. Every experience matters.
